MiniMed Faces FDA Panel For Consumer Glucose Sensor; Dampens Outlook
This article was originally published in The Gray Sheet
Executive Summary
MiniMed's home-use continuous glucose monitoring system (CGMS) could be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Panel as early as May 9, the company says.